Mirum Pharmaceuticals, a biopharmaceutical company, completed the acquisition of Satiogen Pharmaceuticals, a specialty pharma company. Financial terms were not disclosed. “The acquisition of Satiogen is a strategic step that consolidates the economics of our commercial and pipeline programs. The Satiogen team laid some of the foundational groundwork for the potential for IBAT inhibitors in liver disease that is now translating to substantial benefits for patients and a successful launch of LIVMARLI in Alagille syndrome. We thank the Satiogen team as we build on their work to continue to advance important therapies for rare disease,” Chris Peetz, Mirum President and Chief Executive Officer.